Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 9/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322988 | 1.00 | KDM4E (0.41) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL14163218 | 0.93 | KDM4E (0.40) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL1324357 | 0.92 | PPARG (0.34) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL1324355 | 0.92 | PPARG (0.34) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL1323852 | 0.90 | PPARG (0.36) | KDM4ESMN1; SMN2HTTPPARGMAPT | |
| SCHEMBL1323853 | 0.90 | PPARG (0.36) | KDM4ESMN1; SMN2HTTPPARGMAPT | |
| SCHEMBL1323157 | 0.90 | MAPT (0.37) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL1323163 | 0.90 | MAPT (0.37) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL2210167 | 0.89 | KDM4E (0.40) | KDM4ESMN1; SMN2HTTALDH1A1PPARG | |
| SCHEMBL2213976 | 0.89 | KDM4E (0.40) | KDM4ESMN1; SMN2HTTALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| EP-2086938-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008073306-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | KDM4E 3048/4885SMN1; SMN2 1520/4885HTT 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.